NervGen Pharma Corp. (OTCQB: NGENF | TSXV: NGEN): Virtual Investor Conferences

About this Video

• Video Title: NervGen Pharma Corp. (OTCQB: NGENF | TSXV: NGEN): Virtual Investor Conferences
• Channel: OTC Markets Group
• Speakers: Mike Kelly (President and CEO), Bill Adams (CFO)
• Duration: 00:30:28

Introduction

This video presents a virtual investor conference showcasing NervGen Pharma Corp., a clinical-stage biotechnology company focused on developing treatments for nervous system damage. The presentation highlights their lead product candidate, NVG291, and its progress in clinical trials for spinal cord injury, along with a preview of their next program, NVG300.

Key Takeaways

• NVG291's mechanism: Targets CSPGs and PTPσ, molecules inhibiting nervous system repair, to facilitate regeneration.
• Extensive preclinical data: Demonstrates NVG291's effectiveness across various nervous system injury models (spinal cord injury, stroke, multiple sclerosis, optic nerve).
• Phase 1b/2a trial progress: A 16-week study (12 weeks treatment, 4 weeks observation) is underway at Shirley Ryan AbilityLab, evaluating NVG291 in both subacute and chronic spinal cord injury patients. The chronic cohort completed enrollment in December, with data expected in late May/early June.
• Trial design and endpoints: The trial measures motor evoked potential (connectivity) as the primary endpoint and functional improvements as secondary endpoints, complemented by qualitative patient interviews.
• NVG300 update: Preclinical data for this next-generation product candidate will be released at the end of the month.